Partial-brain radiotherapy for XXXX : multi-institutional experience.

@entity1 @entity1499 @entity149 @entity2359
UNASSIGNED: Whole-brain radiotherapy (WBRT) has been an important component of treatment for @entity149 ( @entity149 ), but delayed @entity2359 has been a matter of concern. We have employed partial-brain radiotherapy (PBRT) with wide margins for @entity149 @entity1 with a single lesion or a few lesions. In this study, we evaluated the treatment outcome in @entity149 @entity1 undergoing PBRT. Between 2003 and 2014, 24 @entity1 were treated with PBRT; 16 received high-dose- @entity1499 (MTX) -containing chemotherapy before PBRT. Conventional fractionation with a median dose of 54 Gy was used. For reference, 15 @entity1 undergoing MTX-based chemotherapy and WBRT were also analyzed. The 3-year overall survival rate was 60% for all 24 @entity1 undergoing PBRT and 68% for the 16 @entity1 undergoing MTX-based chemotherapy plus PBRT. The 3-year progression-free survival rate was 41% for all 24 @entity1 undergoing PBRT and 36% for the 16 @entity1 undergoing MTX-based chemotherapy. The in-field recurrence rate was 26% and the out-of-field recurrence rate was 15% at 3 years for all 24 @entity1 undergoing PBRT. The rates for in-field recurrence and the out-of-field recurrence were 27% and 21%, respectively, for the 16 @entity1 undergoing MTX-based chemotherapy. CNS-recurrence rates were similar in @entity1 undergoing MTX-based chemotherapy and PBRT to the rates in those undergoing MTX-based chemotherapy and WBRT. @entity149 developed in 3 of the 16 @entity1 undergoing MTX + PBRT and in 4 of 15 @entity1 undergoing MTX + WBRT (P = 0.68). PBRT seems to be a feasible treatment option for solitary @entity149 . Further investigations are warranted to evaluate the advantages of PBRT over WBRT.
